Pantoprazole | The control of the tablet is coated. 40 mg, 14 pcs.

Release form

coated tablets

Packing

14 pcs

Pharmacological action

Control - inhibitory proton pump.

Inhibitor of the proton pump (H + -K + -ATPase). Blocks the final stage of hydrochloric acid secretion, reducing basal and stimulated secretion, regardless of the nature of the stimulus.

Antisecretory activity. After oral administration of 20 mg of the drug Controlok®, the antisecretory effect occurs after 1 hour and reaches a maximum after 2–4 hours. With iv administration of 80 mg, the antisecretory effect reaches a maximum within 1 hour and lasts 24 hours. In case of duodenal ulcer associated with Helicobacter pylori, decreased gastric secretion increases the sensitivity of microorganisms to antibiotics. Does not affect the motility of the digestive tract. Secretory activity is normalized 3-4 days after the end of the dose.

Compared to other proton pump inhibitors, the Controlok® drug has greater chemical stability at neutral pH, and less potential for interaction with the liver oxidase system, which depends on cytochrome P450.aerial preparations.

Indications

Peptic ulcer of the stomach and duodenum (in the acute phase), erosive gastritis (including those associated with NSAIDs).

Gastroesophageal reflux disease (GERD): treatment of erosive reflux esophagitis, symptomatic treatment of non-erosive reflux disease (NERD).

Zollinger-Ellison Syndrome.

Eradication of Helicobacter pylori in combination with antibacterial agents.

Treatment and prevention of stress ulcers, as well as their complications in the form of bleeding, perforation, penetration (for solution for iv administration).

Contraindications

Hypersensitivity to dyspepsia of neurotic origin (tablets).

Precautions: pregnancy, lactation, liver failure.

Use during pregnancy and lactation

Control should be used with caution during pregnancy and lactation.

Composition

1 tablet contains:

Active ingredients: pantoprazole sodium sesquihydrate 22.57 mg (corresponding to 20 mg pantoprazole) sodium sesquihydrate 45.1 mg (corresponding to 40 mg pantoprazole)

Excipients: sodium calcium carbonate water-free anhydrous purified

Shell: hypromellose 2910 povidone K25 titanium dioxide (E171) iron oxide yellow (E172) propylene glycol eudragit L 30D-55 (methacrylic acid and ethyl acrylate copolymer, polysorbate 80, sodium lauryl sulfate) triethylcyl spending

Dosage and administration

Inside, washed down with liquid and swallowed whole (tablets cannot be crushed or dissolved).

Peptic ulcer of the stomach and duodenum, erosive gastritis (including those associated with NSAIDs): 40–80 mg / day. The course of treatment is 2 weeks for exacerbation of duodenal ulcer and 4-8 weeks for exacerbation of gastric ulcer. Anti-relapse treatment of peptic ulcer of the stomach and duodenum - 20 mg / day.

Eradication of Helicobacter pylori. The following combinations are recommended:

Control® 20 mg 2 times a day + amoxicillin 1000 mg 2 times a day + clarithromycin 500 mg 2 times a day

Control® 20 mg 2 times a day + metronidazole 500 mg 2 times a day day + clarithromycin 500 mg 2 times a day

Control® 20 mg 2 times a day + amoxicillin 1000 mg 2 times a day + metronidazole 500 mg 2 times a day.

The course of treatment is 7-14 days.

Reflux esophagitis: 20–40 mg / day. The course of treatment is 4-8 weeks. Anti-relapse treatment - 20 mg / day.

Zollinger-Ellison Syndrome: 40–80 mg / day. In patients with severe hepatic impairment, the dose should be reduced to 40 mg once every 2 days. In this case, it is necessary to control the biochemical parameters of the blood. With an increase in the level of liver enzymes, the use of the drug should be discontinued.

Older patients, as well as patients with impaired renal function, should not exceed a daily dose of 40 mg. An exception is the use of combination antimicrobial therapy against Helicobacter pylori, when elderly patients should use the drug Controlok 40 mg 2 times a day.

According to indications requiring taking the drug once a day, the drug Controlok® should be taken in the morning. It was established that neither the time of day, nor food intake affects the activity of the drug, but the recommended time for taking Controlok® tablets contributes to better patient compliance with the treatment regimen.

Side effects

Typical: upper abdominal pain, diarrhea, constipation, flatulence headache.

Atypical: nausea / vomiting, dizziness, blurred vision (blurred vision), allergic reactions such as pruritus and skin rash.

Rare: dry mouth, arthralgia, depression, hallucinations, disorientation and confusion, especially in patients predisposed to this, as well as an increase in these symptoms if patients have previously observed them.

Very rare: leukopenia, thrombocytopenia thrombophlebitis at the injection site (powder for solution for iv) peripheral edema severe hepatocellular damage, anaphylactic reactions leading to jaundice with or without liver failure, including anaphylactic shock, increased liver enzymes (transaminases, glutamyl transpeptidases), increased triglycerides, increased body temperature, myalgia, interstitial nephritis, urticaria, angioedema severe skin reactions such as Stevens Johnson's sensitivity, light sensitivity, Johnson's sensitivity Lyell's syndrome.

Drug Interaction

Concurrent administration of Kontrolok® may reduce the absorption of drugs whose bioavailability depends on the pH of the gastric medium (eg iron salts, ketoconazole).

Kontrolok®, unlike other proton pump inhibitors, can be prescribed without the risk of drug interaction:

patients with cardiovascular diseases receiving cardiac glycosides (digoxin), BKK (nifedipine), -adrenoblockers (metoprolol) patients antacids, antibiotics (amoxicillin, clarithromycin)

to patients taking oral contraceptives

to patients, accepting NSAIDs (diclofenac, pheroxone, naproxen)

patients with endocrine disorders, patients receiving lebothyroxine patients as warfarin and fenprocoumon

to patients who underwent transplantation receiving cyclosporine, tacrolimus.

There was also a lack of drug interaction with theophylline, caffeine and ethanol.

Interaction with atazanavir and ritonavir (tablets) is possible.

Overdose

To date, no overdose has been reported with the use of the drug. Doses up to 240 mg were administered in / over for 2 min and were well tolerated. However, in case of overdose and only in the presence of clinical manifestations (possible increase of side effects) is carried out symptomatic and supportive treatment. Pantoprazole is not excreted by hemodialysis.

Storage conditions

At a temperature not exceeding 25 РC.

The Expiration of

is 3 years.

Deystvuyuschee substances

Pantoprazole

Pharmacy terms

Prescription

dosage form

drug venal form

tablets

Takeda GmbH, Japan